Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 24, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

February 1, 2026

Conditions

Mesothelioma, MalignantCarcinoma, Non-Small-Cell LungCarcinoma Breast Stage IVOvarian CancerEsophageal CancerGastric Cancer

Interventions

DRUG

Cisplatine Teva®

PITHAC: Cisplatin (Cisplatine Teva®) at a dose between 7.5 and 70 mg/m2 of body surface at a temperature of 39±1°C

Trial Locations (1)

RECRUITING

Centre Hospitalier Universitaire Vaudois, Lausanne

All Listed Sponsors

lead

Dr Jean Yannis PERENTES

OTHER